Evicenter
MarkdownMedical informationP&T meetings
Lonimecgene renparvovec (TSHA-102)

Rett syndrome

Launch
Not announced
Last updated
199 sources

Section 1 of 6

Terms and abbreviations

1 evidence topic · 0 sources

AbbreviationTerm
10-KAnnual report filed with the U.S. Securities and Exchange Commission
10-QQuarterly report filed with the U.S. Securities and Exchange Commission
25-OH25-hydroxy (vitamin D)
AACAugmentative and alternative communication
AAVAdeno-associated virus
AAV2Adeno-associated virus serotype 2
AAV9Adeno-associated virus serotype 9
aBMDAreal bone mineral density
AEAdverse event
AEDAntiepileptic drug
AHFSAmerican Hospital Formulary Service
ARSDAustralian Rett Syndrome Database
AUDAustralian dollars
BDNFBrain-derived neurotrophic factor
BIABudget impact analysis
BIDTwice daily
BiPAPBilevel positive airway pressure
BLABiologics License Application
BMCBone mineral content
BMDBone mineral density
BMIBody mass index
BSCBest supportive care
CADCanadian dollars
CarerQol-7DCare-related Quality of Life instrument, seven dimensions
CBDCannabidiol
CDA-AMCCanada's Drug Agency (L'Agence des médicaments du Canada)
CDKL5Cyclin-dependent kinase-like 5
CGIClinical Global Impression
CGI-IClinical Global Impression-Improvement
CGI-SClinical Global Impression-Severity
CHQ-PF50Child Health Questionnaire Parent Form 50
CHUCentre hospitalier universitaire (university hospital centre)
CIConfidence interval
CMCChemistry, manufacturing, and controls
CNSCentral nervous system
CNVCopy number variant
COAClinical outcome assessment
COECenter of excellence
CPTCurrent Procedural Terminology
CROCaregiver-reported outcome
CSFCerebrospinal fluid
CTAClinical trial application
DCEDiscrete choice experiment
DEXADual-energy X-ray absorptiometry
DIMSDisorders of initiating and maintaining sleep
DLTDose-limiting toxicity
DMDevelopmental milestone
DMADevelopmental Milestones Assessment
DMPADepot medroxyprogesterone acetate
DNADeoxyribonucleic acid
DNMT3DNA methyltransferase 3
DRGDorsal root ganglion
DTCDelayed treatment cohort
DXADual-energy X-ray absorptiometry
ECGElectrocardiogram
EDEmergency department
EKGElectrocardiogram
EMAEuropean Medicines Agency
EPAREuropean public assessment report
EQ-5D-5LEuroQol 5-dimension, 5-level questionnaire
EUEuropean Union
FDAU.S. Food and Drug Administration
FL-MeCP2Full-length methyl-CpG-binding protein 2
FOXG1Forkhead box G1
FTDFast Track designation
GABAGamma-aminobutyric acid
GERDGastroesophageal reflux disease
GFAPGlial fibrillary acidic protein
GFPGreen fluorescent protein
GIGastrointestinal
GMPGood manufacturing practice
GTCGeneralized tonic-clonic
H2Histamine-2 (receptor)
HCPHealthcare professional
HCRUHealthcare resource utilization
HRHazard ratio
HRUHealthcare resource utilization
HSHand stereotypies
I2I-squared statistic of heterogeneity
ICERIncremental cost-effectiveness ratio
ICHInternational Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
ICMIntracisterna magna
ICVIntracerebroventricular
IDMCIndependent Data Monitoring Committee
ILAPInnovative Licensing and Access Pathway
INDInvestigational New Drug application
INNInternational Nonproprietary Name
IQRInterquartile range
IRSFInternational Rett Syndrome Foundation
ISCDInternational Society for Clinical Densitometry
ITIntrathecal
ITCImmediate treatment cohort
ITRInverted terminal repeat
IUInternational units
JNDAJapanese New Drug Application
KOKnockout
LPLumbar puncture
LRTILower respiratory tract infection
LSLeast squares
LSMLeast squares mean
MAAMarketing authorization application
MADMaximum administered dose
MBAMotor Behavior Assessment
MBDMethyl-CpG-binding domain
MCGRMagnetically controlled growing rods
MCSMental component score
MCSFMonthly countable seizure frequency
MDSMECP2 duplication syndrome
MeCP2Methyl-CpG-binding protein 2
MECP2Methyl-CpG-binding protein 2 gene
MHRAMedicines and Healthcare products Regulatory Agency
MIMMendelian Inheritance in Man
miRAREMicroRNA-responsive autoregulatory element
miRNAMicroRNA
MLPAMultiplex ligation-dependent probe amplification
mRNAMessenger ribonucleic acid
MSEL-AMullen Scales of Early Learning, adapted
MTDMaximum tolerated dose
NCoRNuclear receptor corepressor
NCVNerve conduction velocity
NfLNeurofilament light chain
NGSNext-generation sequencing
NHPNonhuman primate
NHSNatural History Study; National Health Service
NIDNCoR/SMRT interaction domain
NIHNational Institutes of Health
NINDSNational Institute of Neurological Disorders and Stroke
NMSNeuromuscular scoliosis
NOLNo Objection Letter
OPOutpatient
ORCAObserver-Reported Communication Ability
OTOccupational therapy
PABAKPrevalence-adjusted bias-adjusted kappa
PCRPolymerase chain reaction
PCSPhysical component score
PedsQLPediatric Quality of Life Inventory
PEPPositive expiratory pressure
PGI-IParental Global Impressions-Improvement
PPPYPer patient per year
PPQProcess performance qualification
PRVPriority review voucher
PSFPosterior spinal fusion
PTPhysical therapy
QALYQuality-adjusted life-year
QoLQuality of life
QTcCorrected QT interval
R-MBARevised Motor Behavior Assessment
rAAV9Recombinant adeno-associated virus serotype 9
RASRett syndrome-associated scoliosis
RDH1Replication dependent histone 1
REMRapid eye movement
REMSRisk Evaluation and Mitigation Strategy
RFRespiratory failure
RMATRegenerative Medicine Advanced Therapy
RNARibonucleic acid
RNHSRett Natural History Study
RoARoute of administration
RS-DMARett Syndrome Developmental Milestone Assessment
RSBQRett Syndrome Behaviour Questionnaire
RSGMSRett Syndrome Gross Motor Scale
RTTRett syndrome
SAESerious adverse event
SAPStatistical analysis plan
scAAV9Self-complementary adeno-associated virus serotype 9
SDStandard deviation
SEStandard error
SECU.S. Securities and Exchange Commission
SF-36v236-Item Short Form Health Survey, version 2
SLRSystematic literature review
SMRTSilencing mediator of retinoic acid and thyroid hormone receptor
ssAAV9Single-stranded adeno-associated virus serotype 9
SSRISelective serotonin reuptake inhibitor
STSpeech therapy
TEAETreatment-emergent adverse event
TMTamoxifen
TRDTranscriptional repression domain
TROFTrofinetide
UKUnited Kingdom
ULNUpper limit of normal
UNIIUnique Ingredient Identifier
USUnited States
USANUnited States Adopted Name
USDU.S. dollars
UTRUntranslated region
vgVector genomes
WHOWorld Health Organization
WTWild type
XCIX-chromosome inactivation
YOAYears of age
ZAZoledronic acid